Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer: Comparison of Current Guidelines and Recommendations Raj Persad, Donald Lamm,

Slides:

Advertisements

Similar presentations

Volume 70, Issue 2, Pages (August 2016)

Advertisements

Volume 68, Issue 4, Pages (October 2015)

Volume 63, Issue 3, Pages (March 2013)

Pascal Rischmann European Urology Supplements

Local Breast Cancer Recurrence after Mastectomy and Breast-Conserving Surgery for Paget's Disease: A Meta-Analysis Breast Care 2014;9: DOI: /

Volume 64, Issue 3, Pages (September 2013)

Increased risk of bladder cancer with pioglitazone therapy in patients with diabetes: A meta-analysis Zhaowei Zhu, Zhoujun Shen, Yingli Lu, Shan Zhong,

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Volume 57, Issue 1, Pages (January 2010)

Treatment Strategies in Advanced Prostate Cancer/Genitourinary Malignancies: The Use of Bisphosphonates Across the Continuum John M. Fitzpatrick, Marc.

The Role of Tobacco Smoke in Bladder and Kidney Carcinogenesis: A Comparison of Exposures and Meta-analysis of Incidence and Mortality Risks Marcus G.

Volume 59, Issue 3, Pages (March 2011)

Contemporary Management of the Painful Bladder: A Systematic Review

Volume 61, Issue 1, Pages (January 2012)

Maintenance Bacillus Calmette-Guérin: The Standard of Care for the Prophylaxis and Management of Intermediate- and High-Risk Non–Muscle-Invasive Bladder.

Volume 61, Issue 5, Pages (May 2012)

Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer Marc Colombel, Mark Soloway, Hideyuki Akaza, Andreas Böhle, Joan Palou, Roger.

Volume 71, Issue 6, Pages e171-e172 (June 2017)

Bladder Cancer: Management and Future Directions

Ashish M. Kamat, Sima Porten European Urology

Volume 73, Issue 5, Pages (May 2018)

Epidemiology, Staging, Grading, and Risk Stratification of Bladder Cancer Marc Colombel, Mark Soloway, Hideyuki Akaza, Andreas Böhle, Joan Palou, Roger.

Treatment of Advanced and Metastatic Renal Cancer: A Revolution?

Bladder Cancer: A Major Public Health Issue

Volume 71, Issue 6, Pages (June 2017)

What is New in Bladder Cancer Diagnosis and Management?

New Trends in Bladder Cancer Management

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.

The Importance of Transurethral Resection in Managing Patients With Urothelial Cancer in the Bladder: Proposal for a Transurethral Resection of Bladder.

Volume 60, Issue 4, Pages (October 2011)

Long-Term Management of Overactive Bladder with Antimuscarinic Agents

Clinical Practice Recommendations for the Management of Non–Muscle Invasive Bladder Cancer Donald Lamm, Marc Colombel, Raj Persad, Mark Soloway, Andreas.

Counselling the Prostate Cancer Patient

Yuanshan Cui, Yong Zhang European Urology

Current Status of Combined Radiation Therapy and Androgen Suppression in Locally Advanced Prostate Cancer: What Is the Way Forward? Michel Bolla European.

Long-term Cancer-specific Survival in Patients with High-risk, Non–muscle-invasive Bladder Cancer and Tumour Progression: A Systematic Review Sven van.

Volume 70, Issue 2, Pages (August 2016)

Volume 67, Issue 6, Pages (June 2015)

Volume 68, Issue 4, Pages (October 2015)

Volume 50, Issue 3, Pages (September 2006)

Optimal Control of Testosterone: A Clinical Case-Based Approach of Modern Androgen- Deprivation Therapy Bertrand Tombal, Richard Berges European Urology.

Perioperative Blood Transfusion Is Associated With Worse Clinical Outcomes in Resected Lung Cancer Ting Wang, MD, Lili Luo, MD, He Huang, MD, Jingrui.

Systematic review or meta-analysis

The Importance of Testosterone Control in Prostate Cancer

Insights into the Relationships between Prostatic Disorders and Their Potential Impact on Future Urologic Practice Claus Roehrborn European Urology.

Long-Term Hormonal Therapy: Who Would Benefit?

Bladder Cancer: Highlights from 2006

Yousef Rezaei, MD American Journal of Kidney Diseases

Volume 71, Issue 3, Pages (March 2017)

New Trends in Managing the Prostate Cancer Patient

Improving Outcomes in Prostate Cancer: Time to Tackle Bone Disorders

Preventing Osteoporosis in Men Taking Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-Analysis Joseph Sargon Joseph, Vincent.

How Do New Data from Clinical Trials Allow Us to Optimise the Assessment and Treatment of Patients with Benign Prostatic Hyperplasia? Vincenzo Mirone

Axel Heidenreich European Urology Supplements

Volume 52, Issue 4, Pages (October 2007)

Clinical Practice Recommendations for the Prevention and Management of Intravesical Therapy–Associated Adverse Events J. Alfred Witjes, Joan Palou, Mark.

Prognostic Factors in Non–Muscle-Invasive Bladder Tumors

Treatment Options in Prostate Cancer Once Primary Therapy Fails

Early Single-Instillation Chemotherapy Has No Real Benefit and Should Be Abandoned in Non–Muscle-Invasive Bladder Cancer Sten Holmäng European Urology.

Jon S. Matsumura, MD, Adnan Z. Rizvi, MD Journal of Vascular Surgery

Clinical Management of Patients Receiving Tyrosine Kinase Inhibitors for Advanced Renal Cell Carcinoma Jan Roigas European Urology Supplements Volume.

Joaquim Bellmunt European Urology Supplements

Emmanuel Chartier-Kastler, Andrea Tubaro European Urology Supplements

New Research Findings on Clinical Benefits of Bisphosphonates in Patients With Advanced Prostate Cancer Noel W. Clarke European Urology Supplements

Jan Roigas European Urology Supplements

Axel Heidenreich European Urology Supplements

Volume 54, Issue 1, Pages (July 2008)

European Urology Oncology

Maximilian Burger, Ashish M. Kamat, David McConkey

Morgan Rouprêt, Per-Uno Malmstrom, Peter Black

Presentation transcript:

Current Approaches to the Management of Non-Muscle Invasive Bladder Cancer: Comparison of Current Guidelines and Recommendations Raj Persad, Donald Lamm, Maurizio Brausi, Mark Soloway, Joan Palou, Andreas Böhle, Marc Colombel, Hideyuki Akaza, Roger Buckley, J. Alfred Witjes European Urology Supplements Volume 7, Issue 10, Pages 637-650 (October 2008) DOI: 10.1016/j.eursup.2008.07.007 Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 1 (a) Forest plot of tumour progression by treatment method. (b) Forest plot of tumour progression by disease type. BCG=bacillus Calmette-Guérin; TUR=transurethral resection; OR=odds ratio; CI=confidence interval; SD=standard deviation; maint=maintenance BCG therapy; MMC=mitomycin C; CIS=carcinoma in situ; O–E=observed number of progressions minus expected number of progressions; Var=variance. Reprinted with permission from the American Urological Association [17]. European Urology Supplements 2008 7, 637-650DOI: (10.1016/j.eursup.2008.07.007) Copyright © 2008 European Association of Urology Terms and Conditions

Fig. 2 (a) Tumour recurrence (all studies) with odds ratio as effect size. (b) Tumour recurrence (all studies by maintenance) with odds ratio as effect size. (c) Forest plot of tumour recurrence (all studies by maintenance and risk group) with odds ratio as effect size. BCG=bacillus Calmette-Guérin; Mainten=BCG maintenance regimen; interm=intermediate; OR=odds ratio; Lower, Upper=lower and upper 95% CI of OR; P=p value (2-sided); Ntotal=total sample size; n/N=number of events per number of cases in treatment group; Fixed=fixed effect model; Random=random effect model; MMC=mitomycin C Lines indicate 95% CI and squares indicate OR estimates, whereas square size is proportional to sample size, and rhombs meta-analytically pooled OR estimates ± 95% CI. Reprinted with permission from the American Urological Association [19]. European Urology Supplements 2008 7, 637-650DOI: (10.1016/j.eursup.2008.07.007) Copyright © 2008 European Association of Urology Terms and Conditions